Table 3.
Cox proportional hazard model for all-cause mortality in the overall sample of patients with anaplastic thyroid carcinoma treated by radiotherapy.
| Variables | Univariate Analysis | Multivariate Analysis | ||
|---|---|---|---|---|
| HR (95% CI) | p-Value | HR (95% CI) | p-Value | |
| Age (years) | 1.00 (0.97–1.04) | 0.819 | - | - |
| Sex (male) | 1.18 (0.56–2.48) | 0.661 | - | - |
| Size (cm) | 1.23 (0.99–1.52) | 0.059 | 0.86 (0.64–1.16) | 0.328 |
| Stage (IVC) | 3.59 (1.59–8.07) | 0.002 | 2.97 (0.81–10.95) | 0.102 |
| Surgery | 0.21 (0.09–0.50) | <0.001 | 0.70 (0.24–2.03) | 0.507 |
| Systemic treatment | ||||
| Cytotoxic CTx | 1.57 (0.74–3.33) | 0.238 | - | - |
| TKI | 0.76 (0.33–1.72) | 0.506 | - | - |
| Multimodal therapy | 0.36 (0.16–0.84) | 0.018 | 0.42 (0.10–1.77) | 0.236 |
| EQD210(≥60 Gy) | 0.10 (0.03–0.31) | <0.001 | 0.27 (0.06–1.22) | 0.089 |
| NLR (≥3.47) | 3.32 (1.51–7.29) | 0.003 | 3.18 (1.15–8.85) | 0.026 |
CI, confidence interval; CTx, chemotherapy; EQD210, equivalent dose in 2-Gy fractions with an α/β ratio of 10; HR, hazard ratio; NLR, neutrophil-to-lymphocyte ratio; TKI, tyrosine kinase inhibitor.